AstraZeneca buys Bristol out of diabetes venture

20-12-2013

Biopharmaceutical company AstraZeneca has paid $4.1 billion to acquire Bristol Myers Squibb’s share of the firms’ diabetes business venture.


astrazeneca, bristol-myers squibb, diabetes, Amylin Pharmaceuticals

LSIPR